BRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration

Reuters04-22

April 22 (Reuters) - Neurosense Therapeutics Ltd

* NEUROSENSE AND GENETIKA+ INITIATE PRECISION MEDICINE COLLABORATION BEGINNING WITH ONGOING PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE

* NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429239699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-22 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429239699","market":"us","top_or_hot":-1,"title":"BRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration","media":"Reuters","content":"<html><body><p>April 22 (Reuters) - <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a></p><p> :</p><p>   * NEUROSENSE AND GENETIKA+ INITIATE PRECISION MEDICINE COLLABORATION BEGINNING WITH ONGOING PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE</p><p>   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPY</p><p>   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 22 (Reuters) - Neurosense Therapeutics Ltd :   * NEUROSENSE AND GENETIKA+ INITIATE PRECISION MEDICINE COLLABORATION BEGINNING WITH ONGOING PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2429239699","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429239699","pubTimestamp":1713789362,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 22  - Neurosense Therapeutics Ltd :   * NEUROSENSE AND GENETIKA+ INITIATE PRECISION MEDICINE COLLABORATION BEGINNING WITH ONGOING PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPY   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPYSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd","BK4139":"生物科技"},"translate_title":"简介—Neurosense与Genetika+开展精准医疗合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"April 22 (Reuters) - Neurosense Therapeutics Ltd :   * NEUROSENSE AND GENETIKA+ INITIATE PRECISION MEDICINE COLLABORATION BEGINNING WITH ONGOING PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPY   * NEUROSENSE THERAPEUTICS: STUDY EXPECTED TO REVEAL SAFETY OF PRIMEC IN AD, AND SHED LIGHT ON EFFICACY, BIOLOGICAL ACTIVITY OF COMBINATION THERAPYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429239699"}